Journal article
Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke
AJ Yoo, KN Sheth, WT Kimberly, ZA Chaudhry, JJ Elm, S Jacobson, SM Davis, GA Donnan, GW Albers, BJ Stern, RG González
Journal of Stroke and Cerebrovascular Diseases | ELSEVIER SCIENCE BV | Published : 2013
Abstract
Background: There is no validated neuroimaging marker for quantifying brain edema. We sought to test whether magnetic resonance imaging (MRI)-based metrics would reliably change during the early subacute period in a manner consistent with edema and whether they would correlate with relevant clinical endpoints. Methods: Serial MRI studies from patients in the Echoplanar Imaging Thrombolytic Evaluation Trial with initial diffusion-weighted imaging (DWI) lesion volume >82 cm3 were analyzed. Two independent readers outlined the hemisphere and lateral ventricle on the involved side and calculated respective volumes at baseline and days 3 to 5. We assessed interrater agreement, volume change betwe..
View full abstractGrants
Awarded by Merck Co
Funding Acknowledgements
Dr. Yoo has received support from Penumbra, Inc for core imaging laboratory activities. Dr. Sheth is supported by research funding from the American Academy of Neurology Clinical Research Award, American Heart Association Clinical Research Award, and Remedy Pharmaceuticals, Inc. Dr. Kimberly is supported by an American Academy of Neurology Clinical Research Award, Clinical Investigator Training Program: Beth Israel Deaconess Medical Center, Harvard Medical School, in collaboration with Pfizer, Inc and Merck & Co (NIH 1K23NS076597). Mr. Jacobson is the CEO of Remedy Pharmaceticals. Dr. Davis serves on the advisory boards of PAION, Servier, and Novo Nordisk, and has received honoraria from Novo Nordisk, Sanofi-Aventis, Pfizer, and Boehringer Ingelheim. Dr. Donnan serves on the advisory boards of Boehringer Ingelheim, PAION, Servier, and Sanofi-Aventis; has received honoraria or consulting payments from and has had costs of participating in scientific meetings reimbursed by Boehringer Ingelheim, Sanofi-Aventis, and Servier; and has received grant funding from Sanofi-Aventis and grants and consultancy payments from Boehringer Ingelheim. Dr. Albers has received grant funding from the National Institutes of Health and Lundbeck; is a consultant for Lundbeck; and holds equity in iSchema View. Dr. Stern is supported by the National Institutes of Health. Drs. Chaudhry, Elm, and Gonzalez have no conflicts of interest to declare.